(6R)-6-(2-ethoxyethoxymethyl)piperidin-2-one | 802907-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (6R)-6-(2-ethoxyethoxymethyl)piperidin-2-one
• CAS: 802907-48-8
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.266
• InChiKey: WRHMFLQSZNTAAX-SECBINFHSA-N

物化性质

• 沸点：
  348.0±12.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6R)-6-(2-ethoxyethoxymethyl)piperidin-2-one 在 dimethyl sulfide borane 、 四丁基氟化铵 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 N,N-二异丙基乙胺 、 potassium iodide 、 lithium chloride 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 生成 6R-(5-cyclopropyl-3S-hydroxy-pent-1E-enyl)-1-(2-hydroxyethyl)-piperidin-2-one
  参考文献：
  名称：

  Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists

  摘要：

  2-Piperidones were prepared bearing heptanoic acid or a thioether heptanoic acid at the I-position as well as appropriately substituted at the 6-position to mimic the structure of prostaglandins. The stereochemical purity at the 6-position was determined to be >= 95% ee for an advanced synthetic intermediate. The 2-piperidones were identified as potent agonists at the EP4 prostanoid receptor. They displayed a high affinity (K-i 5-130 nM) at EP4 and subtype selectivity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.059
• 作为产物：
  描述：

  D-2-氨基己二酸 在 sodium tetrahydroborate 、 溶剂黄146 、 三氟乙酸 作用下， 生成 (6R)-6-(2-ethoxyethoxymethyl)piperidin-2-one
  参考文献：
  名称：

  Lactams as prostanoid receptor ligands. Part 4: 2-Piperidones as selective EP4 receptor agonists

  摘要：

  2-Piperidones were prepared bearing heptanoic acid or a thioether heptanoic acid at the I-position as well as appropriately substituted at the 6-position to mimic the structure of prostaglandins. The stereochemical purity at the 6-position was determined to be >= 95% ee for an advanced synthetic intermediate. The 2-piperidones were identified as potent agonists at the EP4 prostanoid receptor. They displayed a high affinity (K-i 5-130 nM) at EP4 and subtype selectivity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.059

文献信息

• 2-Piperidone derivatives as prostaglandin agonists
  申请人：——

  公开号：US20040142969A1

  公开（公告）日：2004-07-22

  The invention provides compounds of the Formula: 1 wherein m, n, A, X, Y, Z, R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

  这项发明提供了以下式的化合物： 1 其中m、n、A、X、Y、Z、R 1 、R 2 、R 4 、R 6 、R 7 、R 8 、R 9 和R 10 如本文所定义，并且其药学上可接受的盐、溶剂化合物、前药、单一异构体或其拉克米或非拉克米异构体混合物。该发明还提供了制备、包含、以及使用式I化合物的方法。
• Piperidinyl prostaglandin E analogs
  申请人：ALLERGAN, INC.

  公开号：US20040248854A1

  公开（公告）日：2004-12-09

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein X, Y, Z, D and R 3 are as defined in the specification. Also disclosed are compounds comprising 2 or a pharmaceutically acceptable salt or a prodrug thereof; wherein A, X, J, and R 3 are as defined in the specification. Also disclosed are compounds having an &agr; and an &ohgr; chain comprising 3 or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一定剂量的通式I代表的化合物；其中X、Y、Z、D和R3如规范中定义。还披露了包括2或其药用盐或前药的化合物；其中A、X、J和R3如规范中定义。还披露了具有α和ω链的化合物，包括3或其衍生物，如规范中定义，或其药用盐或前药。
• Treatment of inflammatory bowel disease
  申请人：Old W. David

  公开号：US20050171062A1

  公开（公告）日：2005-08-04

  The present invention provides a method of treating inflammatory bowel disease which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula 1; wherein X, Y, Z, D and R 3 are as defined in the specification. Also useful for the treatment of inflammatory bowel disease are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein A, X, J, and R 3 are as defined in the specification. Also useful for the treatment of inflammatory bowel disease are compounds having an α and an ω chain comprising or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof.

  本发明提供了一种治疗炎症性肠病的方法，包括向患有眼压增高或青光眼的动物施用一定疗效的一般式1代表的化合物；其中X、Y、Z、D和R3如规范中所定义。还可用于治疗炎症性肠病的化合物包括或其药用盐或前药；其中A、X、J和R3如规范中所定义。还可用于治疗炎症性肠病的化合物包括具有α和ω链或其衍生物，如规范中所定义或其药用盐或前药。
• PROCESSES FOR PRODUCTION OF NUCLEOSIDES
  申请人：Ajinomoto Co., Inc.

  公开号：EP1589027A1

  公开（公告）日：2005-10-26

  The present invention relates to a production method of a nucleoside compound represented by the formula [II] which includes subjecting a 2',3',5'-triacyloxynucleoside compound represented by the formula [I] to deacylation using alkali metal hydroxide in a 0.01- to 0.5-fold amount in a molar ratio relative to the 2',3',5'-triacyloxynucleoside compound. According to the present invention, a production method of a nucleoside compound of the formula [II] which suppresses a by-product, and a production method of a nucleoside derivative which utilizes this method can be provided. In addition, the present invention relates to oxidation of a nucleoside compound represented by the formula (1) in the presence of a 2,2,6,6-tetramethylpiperidine-1-oxy catalyst, and hypochlorite or hypobromite, while adjusting pH to fall within the range of 5-9, and further, extracting a nucleoside-carboxylic acid compound represented by the formula (2) into an organic solvent under acidic conditions, back-extracting the compound from the organic solvent into an aqueous alkali solution, and neutralizing the aqueous alkali solution by adding an acid thereto to allow precipitation of a crystal. Thus, a highly pure particular nucleoside-carboxylic acid compound or a salt thereof can be produced by a method suitable for industrial production: wherein each symbol is as defined in the Description.

  本发明涉及一种核苷化合物的生产方法，该核苷化合物由式[I]所表示的2',3',5'-三酰氧核苷化合物经过使用在摩尔比为0.01至0.5的碱金属氢氧化物下的去酰化而制得。根据本发明，可以提供一种抑制副产物的核苷化合物的生产方法和利用该方法的核苷衍生物的生产方法。此外，本发明涉及在2,2,6,6-四甲基哌啶-1-氧催化剂和次氯酸盐或次溴酸盐的存在下，将式（1）所表示的核苷化合物氧化，同时将pH调节在5-9的范围内，并在酸性条件下将式（2）所表示的核苷-羧酸化合物提取到有机溶剂中，将化合物从有机溶剂中回萃取到水性碱溶液中，并通过加入酸来中和水性碱溶液以沉淀结晶。因此，可以通过适用于工业生产的方法生产高纯度的特定核苷-羧酸化合物或其盐：其中每个符号如描述中所定义。
• PIPERIDINYL PROSTAGLANDIN E ANALOGS
  申请人：Old W. David

  公开号：US20050164990A1

  公开（公告）日：2005-07-28

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein X, Y, Z, D and R 3 are as defined in the specification.

  本发明提供了一种治疗眼压升高或青光眼的方法，包括向患有眼压升高或青光眼的动物施用一定量的化合物，该化合物由一般式I表示；其中X、Y、Z、D和R3如规范中定义。